NASDAQ:VTVT vTv Therapeutics (VTVT) Stock Forecast, Price & News $0.45 +0.01 (+2.27%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$0.44▼$0.4650-Day Range$0.42▼$0.7452-Week Range$0.41▼$1.05Volume80,239 shsAverage Volume136,285 shsMarket Capitalization$47.07 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media vTv Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,233.0% Upside$6.00 Price TargetShort InterestHealthy4.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.69 out of 5 starsMedical Sector829th out of 962 stocksPharmaceutical Preparations Industry394th out of 451 stocks 3.5 Analyst's Opinion Consensus RatingvTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, vTv Therapeutics has a forecasted upside of 1,233.0% from its current price of $0.45.Amount of Analyst CoveragevTv Therapeutics has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.42% of the float of vTv Therapeutics has been sold short.Short Interest Ratio / Days to CovervTv Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in vTv Therapeutics has recently decreased by 13.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldvTv Therapeutics does not currently pay a dividend.Dividend GrowthvTv Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VTVT. Previous Next 0.7 News and Social Media Coverage News SentimentvTv Therapeutics has a news sentiment score of -0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for vTv Therapeutics this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added vTv Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, vTv Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.80% of the stock of vTv Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.36% of the stock of vTv Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of vTv Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of vTv Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About vTv Therapeutics (NASDAQ:VTVT) StockvTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.Read More VTVT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VTVT Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.comSeptember 18, 2023 | finance.yahoo.comCANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMASeptember 26, 2023 | Altimetry (Ad)Surprising "Twist" Hands Biden Landslide Re-election?This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.September 16, 2023 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.comAugust 24, 2023 | finance.yahoo.comIs vTv Therapeutics Inc (VTVT) Modestly Undervalued?August 16, 2023 | finance.yahoo.comvTv Therapeutics reports $5.6 million net loss as prepares for reverse stock split to remain on NasdaqAugust 12, 2023 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate UpdateAugust 11, 2023 | finance.yahoo.comvTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate UpdateSeptember 26, 2023 | Altimetry (Ad)Surprising "Twist" Hands Biden Landslide Re-election?This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.August 10, 2023 | finance.yahoo.comCantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast CancerAugust 6, 2023 | msn.comNearly half of U.S. adults want weight-loss drugs – KFF pollJuly 12, 2023 | finance.yahoo.comVTVT - vTv Therapeutics Inc.July 6, 2023 | msn.comvTv Therapeutics Inc - (VTVT) Price Target Decreased by 33.33% to 2.04June 16, 2023 | marketwatch.comvTv Therapeutics Partner Licenses Exclusive Rights to Intellectual Property for AzeliragonJune 16, 2023 | tmcnet.comvTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as aJune 16, 2023 | finance.yahoo.comvTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive DeclineJune 15, 2023 | finance.yahoo.comCANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTONJune 6, 2023 | bizjournals.comAs it advances its Type 1 Diabetes treatment, vTv Therapeutics increases cash position, decreases net loss in Q1May 24, 2023 | finance.yahoo.comvTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex PharmaceuticalsMay 12, 2023 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate UpdateMay 12, 2023 | finance.yahoo.comvTv Therapeutics Insider Ups Holding During YearMay 12, 2023 | finance.yahoo.comvTv Therapeutics Insider Ups Holding During Year \May 11, 2023 | finance.yahoo.comvTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate UpdateApril 28, 2023 | morningstar.comvTv Therapeutics Inc Class AApril 20, 2023 | finance.yahoo.comCantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19April 18, 2023 | msn.comPromising Upsides on these Biotech Penny StocksMarch 25, 2023 | finance.yahoo.com3 Pharma Stocks That Could Benefit from Global Healthcare TrendsSee More Headlines Receive VTVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VTVT Company Calendar Last Earnings8/11/2023Today9/25/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTVT CUSIPN/A CIK1641489 Webwww.vtvtherapeutics.com Phone(336) 841-0300Fax336-841-0310Employees13Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+1,221.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,160,000.00 Net MarginsN/A Pretax Margin-272,700.00% Return on EquityN/A Return on Assets-63.74% Debt Debt-to-Equity RatioN/A Current Ratio1.50 Quick Ratio1.50 Sales & Book Value Annual Sales$2.02 million Price / Sales23.51 Cash FlowN/A Price / Cash FlowN/A Book Value($0.10) per share Price / Book-4.54Miscellaneous Outstanding Shares104,580,000Free Float103,740,000Market Cap$47.49 million OptionableNot Optionable Beta-1.13 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Jonathan L. Isaacsohn FACC (Age 69)M.D., Exec. Chairperson Mr. Paul J. Sekhri M.Sc. (Age 65)MSc, CEO, Pres & Director Comp: $483.43kMr. Steven Tuch M.B.A. (Age 54)Exec. VP & CFO Comp: $449.16kMr. Barry Brown (Age 62)Chief Accounting Officer Comp: $311.98kMr. Richard S. Nelson (Age 53)Exec. VP of Corp. Devel. & Director Comp: $201.08kDr. Carmen Valcarce Ph.D.Chief Scientific Officer & Exec. VPVanessa McDadeChief Admin. OfficerMs. Elizabeth M. Keiley (Age 57)Exec. VP & Gen. Counsel More ExecutivesKey CompetitorsAeglea BioTherapeuticsNASDAQ:AGLEAssembly BiosciencesNASDAQ:ASMBSocietal CDMONASDAQ:SCTLDianthus TherapeuticsNASDAQ:DNTHCelularityNASDAQ:CELUView All CompetitorsInsidersJohn A FryBought 20,539 shares on 11/28/2022Total: $17,047.37 ($0.83/share)View All Insider Transactions VTVT Stock - Frequently Asked Questions Should I buy or sell vTv Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VTVT shares. View VTVT analyst ratings or view top-rated stocks. What is vTv Therapeutics' stock price forecast for 2023? 1 brokerages have issued 1 year price objectives for vTv Therapeutics' shares. Their VTVT share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 1,221.3% from the stock's current price. View analysts price targets for VTVT or view top-rated stocks among Wall Street analysts. How have VTVT shares performed in 2023? vTv Therapeutics' stock was trading at $0.6628 on January 1st, 2023. Since then, VTVT shares have decreased by 31.5% and is now trading at $0.4541. View the best growth stocks for 2023 here. When is vTv Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our VTVT earnings forecast. How were vTv Therapeutics' earnings last quarter? vTv Therapeutics Inc. (NASDAQ:VTVT) issued its earnings results on Friday, August, 11th. The biotechnology company reported ($0.07) earnings per share for the quarter. What other stocks do shareholders of vTv Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA). When did vTv Therapeutics IPO? (VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers. What is vTv Therapeutics' stock symbol? vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT." How do I buy shares of vTv Therapeutics? Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is vTv Therapeutics' stock price today? One share of VTVT stock can currently be purchased for approximately $0.45. How much money does vTv Therapeutics make? vTv Therapeutics (NASDAQ:VTVT) has a market capitalization of $47.49 million and generates $2.02 million in revenue each year. The biotechnology company earns $-19,160,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. How can I contact vTv Therapeutics? vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The official website for the company is www.vtvtherapeutics.com. The biotechnology company can be reached via phone at (336) 841-0300, via email at ir@vtvtherapeutics.com, or via fax at 336-841-0310. This page (NASDAQ:VTVT) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.